Jump to content

SLAMF1

From Wikipedia, the free encyclopedia
(Redirected from CD150)

SLAMF1
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesSLAMF1, CD150, CDw150, SLAM, signaling lymphocytic activation molecule family member 1
External IDsOMIM: 603492; MGI: 1351314; HomoloGene: 48162; GeneCards: SLAMF1; OMA:SLAMF1 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

6504

27218

Ensembl

ENSG00000117090

ENSMUSG00000015316

UniProt

Q13291

Q9QUM4

RefSeq (mRNA)

NM_003037
NM_001330754

NM_013730
NM_001360898

RefSeq (protein)

NP_001317683
NP_003028

NP_038758
NP_001347827

Location (UCSC)Chr 1: 160.61 – 160.65 MbChr 1: 171.59 – 171.63 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Signaling lymphocytic activation molecule 1 is a protein that in humans is encoded by the SLAMF1 gene.[5][6] Recently SLAMF1 has also been designated CD150 (cluster of differentiation 150).

SLAMF1 belongs to the signaling lymphocytic activation molecule family. As other receptors from this family, SLAMF1 is expressed in different types of hematopoietic cells and it plays a role in the regulation of the immune system.[7]

Gene

[edit]

The gene encoding SLAMF1 receptor is located on the human chromosome 1. It consists of eight exons and seven introns. Alternative splicing of SLAMF1 transcripts results in several isoforms of the protein, including the conventional transmembrane isoform (mCD150), secreted isoform (sCD150) cytoplasmic isoform (cCD150), and the novel transmembrane isoform (nCD150).[7]

SLAMF1 is expressed in hematopoietic stem cells. It is also used as one of the markers for their identification.[8] Furthermore, its expression was detected in thymocytes, NKT cells, T cells, B cells, monocytes, macrophages and dendritic cells. Monocytes, macrophages and dendritic cells express SLAMF1 after their activation. The activation of T cells and plasma cell differentiation leads to the increased expression of this receptor.[7][8] The interaction of SLAMF1 promoter and enhancers with the Early B-cell factor 1 (EBF1) is required for the expression of SLAMF1 gene in B cells. STAT6, IRF4, and NF-kB factors involved in the transfer of the signals from the B-cell receptor, its co-receptors and IL-4R, also play important role in the regulation of SLAMF1 expression.[9] The expression of SLAMF1 is not restricted to immune cells and their progenitors. From non-immune cells, platelets express SLAMF1.[7][8]

Structure

[edit]

SLAMF1 is a type I transmembrane protein belonging to the immunoglobulin superfamily.[8] Its molecular weight is between 70 kDa and 95 kDa. The extracellular region of the receptor is composed of one Ig variable-like domain and one Ig constant 2-like domain. The intracellular region of the receptor contains two intracellular tyrosine-based switch motives (ITSMs) that interact with SH2 domain-containing proteins. However, nCD150 intracellular region differs from other isoforms of this protein, it lacks ITSMs. sCD150 isoform lacks the transmembrane domain and therefore, it can not be anchored to the cell membrane.[7]

Signaling

[edit]

The receptor SLAMF1 mediates homophilic interactions as most of the receptors from the SLAMF. Signaling from SLAMF1 receptor can be activating or inhibitory. The type of the signal depends on the cell type, differentiation stage, and the combination of signals from other receptors.[7]

SH2 domain-containing proteins, specifically adaptor proteins SAP and EAT-2, and phosphatases SHP-1, SHP-2 and SHIP, interact with ITSMs in the intracellular region of SLAMF1.[7][10] Binding of SAP to ITSMs leads to the activation of the kinase Fyn that phosphorylates tyrosines of SLAMF1 and recruits downstream signaling proteins. Because of the high affinity of SAP to tyrosine phosphorylated ITSMs, it outcompetes the phosphatases which are the mediators of the inhibitory signal. Therefore, the expression and availability of SAP play a crucial role in the determination of the type of the signal.[11][12]

Function

[edit]

SLAMF1 is involved in the regulation of thymocyte development, T cell proliferation, differentiation and T cell function, such as the cytotoxic activity of CD8+ T cells and the production of IL-4, IL-13 and IFNγ. In B cells, it regulates the proliferation and the antibody production.[7][8] SLAMF1 acts as a self-ligand during the interaction between B cells and T cells and promotes lymphocyte activation.[10]

The development of NKT cells is dependent on a signal mediated by SAP. It was found out that the homophilic interaction of SLAMF1 or SLAMF6 is required for SAP recruitment in NKT cells. This interaction mediates a secondary signal crucial for NKT cell differentiation and expansion in the thymus.[13]

SLAMF1 expression in macrophages is associated with killing of Gram-negative bacteria. SLAMF1 acts as a bacterial sensor. It is internalized after the recognition of Gram-negative bacteria, and it plays a role in the regulation of phagosome maturation, ROS and NO production. The absence of SLAMF1 in phagocytes leads, among other things, to the disruption of cytokine production.[13]

Role of SLAMF1 in diseases

[edit]

Viral infections

[edit]

SLAMF1 is a receptor for Morbilliviruses.[7] This genus of viruses includes agents causing measles in humans, rinderpest in cattle and distemper in dogs and cats.[14] Ig variable-like domain of SLAMF1 binds to hemagglutinin on the surface of the virus and this interaction mediates the virus entry into the host cell.[7]

Cancer

[edit]

SLAMF1 is expressed in cancer cells in some types of hematologic malignancies (cutaneous T-cell lymphoma, few types of B-cell non-Hodgkin´s lymphoma, Hodgkin´s lymphoma and about 50 % of chronic lymphocytic leukemia cases).[7] It regulates cancer cell growth and survival by activating PI3K/Akt/mTOR signaling pathway. Therefore, SLAMF1 could be used as a diagnostical and prognostic marker in these cancer types.[8] Several cases of leukemia or Hodgkin´s lymphoma remission after measles virus infection or vaccination have been described. Therefore, SLAMF1 could be used as a target for cancer therapy which is based on the measles virus-mediated lysis of the cancer cells.[7]

nCD150 isoform was found in tumors of the central nervous system, such as glioblastoma, anaplastic and diffuse astrocytoma and ependymoma.[10]

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000117090 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000015316 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Cocks BG, Chang CC, Carballido JM, Yssel H, de Vries JE, Aversa G (July 1995). "A novel receptor involved in T-cell activation". Nature. 376 (6537): 260–263. Bibcode:1995Natur.376..260C. doi:10.1038/376260a0. PMID 7617038. S2CID 4319295.
  6. ^ "Entrez Gene: SLAMF1 signaling lymphocytic activation molecule family member 1".
  7. ^ a b c d e f g h i j k l Gordiienko I, Shlapatska L, Kovalevska L, Sidorenko SP (July 2019). "SLAMF1/CD150 in hematologic malignancies: Silent marker or active player?". Clinical Immunology. 204: 14–22. doi:10.1016/j.clim.2018.10.015. PMID 30616923. S2CID 58586790.
  8. ^ a b c d e f Farhangnia P, Ghomi SM, Mollazadehghomi S, Nickho H, Akbarpour M, Delbandi AA (2023-05-11). "SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy". Frontiers in Immunology. 14: 1174138. doi:10.3389/fimmu.2023.1174138. PMC 10213746. PMID 37251372.
  9. ^ Schwartz AM, Putlyaeva LV, Covich M, Klepikova AV, Akulich KA, Vorontsov IE, et al. (October 2016). "Early B-cell factor 1 (EBF1) is critical for transcriptional control of SLAMF1 gene in human B cells". Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms. 1859 (10): 1259–1268. doi:10.1016/j.bbagrm.2016.07.004. PMID 27424222.
  10. ^ a b c Fouquet G, Marcq I, Debuysscher V, Bayry J, Rabbind Singh A, Bengrine A, et al. (March 2018). "Signaling lymphocytic activation molecules Slam and cancers: friends or foes?". Oncotarget. 9 (22): 16248–16262. doi:10.18632/oncotarget.24575. PMC 5882332. PMID 29662641.
  11. ^ Dragovich MA, Mor A (July 2018). "The SLAM family receptors: Potential therapeutic targets for inflammatory and autoimmune diseases". Autoimmunity Reviews. 17 (7): 674–682. doi:10.1016/j.autrev.2018.01.018. PMC 6508580. PMID 29729453.
  12. ^ Wu N, Veillette A (February 2016). "SLAM family receptors in normal immunity and immune pathologies". Current Opinion in Immunology. 38: 45–51. doi:10.1016/j.coi.2015.11.003. PMID 26682762.
  13. ^ a b van Driel BJ, Liao G, Engel P, Terhorst C (2016-01-20). "Responses to Microbial Challenges by SLAMF Receptors". Frontiers in Immunology. 7: 4. doi:10.3389/fimmu.2016.00004. PMC 4718992. PMID 26834746.
  14. ^ de Vries RD, Duprex WP, de Swart RL (February 2015). "Morbillivirus infections: an introduction". Viruses. 7 (2): 699–706. doi:10.3390/v7020699. PMC 4353911. PMID 25685949.

Further reading

[edit]
[edit]
  • Overview of all the structural information available in the PDB for UniProt: Q13291 (Signaling lymphocytic activation molecule) at the PDBe-KB.
Stub icon

This membrane protein–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=SLAMF1&oldid=1195810150"